title: Typhlitis with concurrent appendicitis in a patient with chronic lymphocytic leukemia.
authors.affiliation: University of Florida Shands Cancer Center, Gainesville, FL 32610, USA. c@ufl.edu
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Cogle
authors.forename: Rebecca M
authors.initials: RM
authors.lastname: Minter
authors.forename: Christine L
authors.initials: CL
authors.lastname: Meyers
authors.forename: W Robert
authors.initials: WR
authors.lastname: Rout
authors.forename: John R
authors.initials: JR
authors.lastname: Wingard
mesh_terms: D000328:Adult; D000074323:Alemtuzumab; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects*; D001064:Appendicitis / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D020345:Enterocolitis, Necrotizing / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D006133:Growth Substances / Q000627:therapeutic use; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications* / Q000188:drug therapy; D008297:Male; D009503:Neutropenia; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D006133:Growth Substances; D000074323:Alemtuzumab